EMEND

There is no image.

Aprepitant

Method of action: Antiemetic

Treatment option: Cancer, Burping, Morning Sickness, Chemotherapy

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of EMEND

Property	Description
Active ingredient	Aprepitant
Form	Hard capsules, Powder for oral suspension
Pharmacological class	Neurokinin-1 (NK₁) Receptor Antagonist
Common use	Proactive prevention of nausea and vomiting
Origin	Synthetic, non-peptidic compound

What Type of Medicine is EMEND?

EMEND is a prescription-only pharmaceutical agent containing the active compound Aprepitant, which functions as an antiemetic agent. It is classified within the pharmacological group of Neurokinin-1 (NK1) Receptor Antagonists, distinguishing it from older anti-sickness medications. The drug is a synthetic, non-peptidic compound delivered for oral administration typically as a hard capsule or as a powder for oral suspension. Aprepitant is characterized by its specificity and high receptor affinity.

What is Aprepitant Used for Generally?

The general purpose of Aprepitant is to provide proactive protection and general therapeutic benefit against severe feelings of sickness and the urge to vomit. Its function relies on the selective high-affinity antagonism of the NK1 receptor. By binding to this receptor, Aprepitant effectively blocks the action of the neuropeptide Substance P, which is a primary chemical messenger for emetic signals in the brain. This describes the medicine's role in providing a more comprehensive, multi-layered anti-sickness defense.

Is EMEND Used Alone or with Other Medicines?

Although Aprepitant is a single active ingredient product, it is most often used as part of a combination therapy. This approach represents a key differentiating factor in its therapeutic strategy, emphasizing cooperative rather than singular action. Its distinct action on the NK1 receptor is complementary to other common antiemetic medications, such as 5-HT3 receptor antagonists and corticosteroids, which target different neurochemical systems. Aprepitant helps augment the efficacy of these co-administered agents, providing a more robust and complete interruption of the emetic process.

What side effects are possible with EMEND?

Possible Side Effects and Safety Information

The safety profile of Aprepitant (EMEND) is established through regulatory classifications that organize documented adverse reactions by frequency and physiological system, as outlined by agencies such as the FDA and EMA. This information is strictly descriptive and non-advisory.

Adverse reactions observed in clinical use are typically classified as common or uncommon. The most common adverse reactions noted in official regulatory documents frequently involve Gastrointestinal Disorders and General Disorders.

Classification	Examples of Documented Reactions
Common	Fatigue, Asthenia (lack of strength), Diarrhea, Dyspepsia (indigestion), Hiccups, Constipation, Increase in ALT (liver enzyme).
Uncommon	Dehydration, Neutropenia (low white blood cell count), Somnolence, Taste disturbance, Rash, Pruritus (itching).

Serious adverse events are also documented. The regulatory safety profile includes the risk of severe, immediate hypersensitivity reactions, including anaphylaxis. Postmarketing surveillance has documented rare reports of severe skin reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis.

Safety Considerations for Specific Contexts:

The label includes explicit safety restrictions and limitations. Use is not recommended in individuals with severe hepatic impairment due to insufficient study data. The regulatory documents also warn that co-administration with specific medications, such as warfarin, requires close monitoring of the International Normalized Ratio (INR), and that the efficacy of hormonal contraceptives may be reduced during and for 28 days following the last dose. Furthermore, chronic continuous administration is officially discouraged as its safety and interaction profile in that context have not been fully studied.

Overdose and Emergency Response

EMEND Overdose and When to Seek Help

Officially documented information regarding human overdose with Aprepitant (EMEND) is limited, with clinical experience primarily reporting symptoms such as drowsiness and headache.

Overdose Scope	Official Regulatory Statements
Documented Presentations	Symptoms have included drowsiness and headache.
Exposure Risks	A primary regulatory concern for elevated exposure is the potential for serious or life-threatening reactions from concomitant medications that are highly sensitive to CYP3A4 inhibition, such as pimozide, cisapride, or terfenadine.
Monitoring Needs	Due to the drug’s high protein binding (greater than 95%), hemodialysis is not expected to be effective for drug removal.

Immediate Action Requirements

The official prescribing information requires that emergency medical attention be sought immediately if an overdose is suspected. Contacting a Poison Control helpline is also mandated. Immediate notification of Emergency Services (911) is required if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Supportive Care and Management

No specific antidote for an Aprepitant overdose is known. Therefore, management must be symptomatic and supportive treatment under continuous clinical observation to manage documented symptoms and monitor for potential secondary toxicities.

Therapeutic Uses of EMEND

What EMEND Treats: Main Uses and Benefits

EMEND (Aprepitant) is commonly used to help manage symptoms related to heightened physiological activity in specific clinical contexts. The medication contributes to easing the overall symptom load and provides support that helps manage symptoms associated with acute or episodic changes.

The medication is commonly used to help prevent the onset of nausea and vomiting associated with chemotherapy regimens that produce significant symptomatic burden, as well as applied in clinical settings that involve acute or unstable symptom patterns to help with symptoms related to postoperative nausea and vomiting (PONV) following certain surgical procedures. In these scenarios, it supports the patient during difficult episodes by easing distress and may assist with maintaining functional stability.

“It is considered relevant for managing symptom clusters that may intensify over time, specifically addressing the delayed phase of sickness.”

This approach is relevant for managing symptom clusters that may become intense or disruptive and may assist with managing both acute and delayed symptom periods.

Quick Fact: Relief for Acute and Delayed Sickness EMEND generally helps manage distressing symptoms across therapeutic domains where additional symptomatic support is needed, primarily focusing on chemotherapy and surgical periods to support the patient during difficult episodes by easing distress.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility for EMEND use is determined by specific regulatory criteria concerning age, concurrent medication use, and certain health conditions.

Contraindications and Restrictions

EMEND is absolutely contraindicated (must not be used) in patients with known hypersensitivity to the drug or those concurrently taking pimozide, terfenadine, astemizole, or cisapride. Co-administration of these medicines is prohibited based on official labeling.

Age-Related Eligibility
Use is established for adults and adolescents 12 years of age and older.
The medicine is indicated for children 6 months of age and older for CINV prevention, with specific formulations (oral suspension) based on age and weight.
Use is not recommended in infants under 6 months as safety and efficacy have not been established.

Conditional Use and Status

Liver Function: Use is not recommended in patients with severe hepatic impairment (Child-Pugh score >9) due to a lack of clinical data. Use is permitted in mild-to-moderate impairment.
Kidney Function: No dosage adjustment is necessary for patients with renal impairment or those with end-stage renal disease on hemodialysis.
Reproductive Status: The medicine is not recommended during pregnancy or lactation due to insufficient human data.
Established Symptoms: EMEND is indicated only for the prevention of nausea and vomiting, and has not been studied for the treatment of established symptoms.

What should I know about interactions with other medicines?

EMEND's interaction profile is governed by its effect as a dose-dependent inhibitor and inducer of the liver enzyme Cytochrome P450 3A4 (CYP3A4), and as an inducer of CYP2C9. This enzyme modulation requires specific prescribing constraints with several drug classes.

Interaction Classification	Interacting Medicines and Products	Regulatory Constraint
Contraindicated (Major)	Pimozide, Terfenadine, Astemizole, Cisapride	Co-administration is explicitly forbidden due to the risk of seriously elevated plasma concentrations and potential life-threatening reactions like QT prolongation.
Requires Monitoring/Adjustment	Warfarin (a CYP2C9 substrate)	International Normalized Ratio (INR) of prothrombin time must be closely monitored for two weeks, particularly at 7 to 10 days, following the start of EMEND therapy.
Requires Adjustment	Dexamethasone or Methylprednisolone	The dose of these co-administered corticosteroids must be reduced (e.g., oral dexamethasone by approximately 50%).
Reduced Efficacy	Hormonal Contraceptives	The effectiveness of hormonal contraceptives (including oral and non-oral forms) may be reduced during administration and for 28 days after the last dose. Alternative non-hormonal contraception methods should be used.

Caution is also advised when EMEND is co-administered with other orally administered CYP3A4 substrates that have a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, or fentanyl, due to the potential for increased drug levels.

Mechanism of Action

Molecular Mechanism: Selective NK1 Receptor Antagonism

The core mechanism of Aprepitant is the selective, high-affinity antagonism of the Neurokinin-1 (NK1) receptor, which is heavily concentrated in the brain's emetic center. . By binding to this receptor, the drug prevents the natural neuropeptide Substance P (SP)—a potent emetic signal—from activating the pathway. This highly targeted molecular action functionally inhibits the SP-mediated signaling system at its origin.

Disruption of the Central Emetic Reflex

Aprepitant's mechanism is intrinsically linked to the central nervous system, where it achieves high receptor occupancy to functionally disrupt the emetic signaling cascade within the brainstem. This central blockade leads to a lowering of the threshold for activation of the emetic reflex. This action maintains inhibition of the neural impulses associated with the prolonged phase of the emetic process.

Mechanistically Complementary Pathway Coverage

Aprepitant's NK1 antagonism provides a mechanistically distinct layer of action that operates in a complementary manner alongside other antiemetic classes, such as 5-HT3 antagonists. This complementary action allows for the simultaneous inhibition of separate neurochemical signaling pathways, contributing to the functional inhibition of the emetic reflex by modulating distinct pathways.

Dosage and Administration Information

Administration Guidelines for EMEND (Aprepitant/Fosaprepitant)

EMEND is a prophylactic antiemetic medication prescribed as part of a multi-drug regimen that must be administered prior to chemotherapy. Its use is defined by specific dosing schedules.

Dosing Schedule and Route of Administration

EMEND is available in oral forms (aprepitant capsules and oral suspension) and an intravenous form (fosaprepitant for injection).

Regimen Context	Day 1 Dose & Timing	Days 2 & 3 Dose & Timing
Oral 3-Day Regimen (Adults)	125 mg capsule orally 1 hour prior to chemotherapy	80 mg capsule orally once daily in the morning
IV Single-Day Regimen (Adults)	150 mg IV infusion over 20 to 30 minutes, completed approx 30 minutes prior to chemotherapy	None
Postoperative Nausea & Vomiting (PONV)	40 mg capsule orally within 3 hours prior to induction of anesthesia	None

Procedural and Age-Specific Rules

Concomitant Therapy: EMEND must be used with a corticosteroid (e.g., dexamethasone) and a 5-HT3 antagonist. The usual dose of dexamethasone is typically reduced by approximately 50% to account for a drug interaction.
Oral Administration: Capsules may be taken with or without food. They should be swallowed whole.
Pediatric Use: For children aged 6 months to less than 12 years, the oral suspension is used, and dosing is weight-based. IV infusion duration varies by age group, requiring 60 minutes for patients 6 months to less than 12 years.
Preparation: Fosaprepitant for injection requires strict reconstitution and further dilution prior to intravenous administration. The oral suspension must also be prepared by a healthcare professional and is administered via an oral dispenser.
Duration: Chronic continuous administration of EMEND is not recommended.

Recent Clinical Evidence

Research Evidence / Overview of Studies for EMEND

Evidence for Use in Chemotherapy-Induced Nausea and Vomiting (CINV)

The clinical evidence for Aprepitant (EMEND) was largely established through pivotal randomized controlled trials (RCTs). These short-term RCTs served to compare regimens containing Aprepitant against control anti-sickness treatments. The research examined outcomes related to systemic or functional imbalance observed with the use of Aprepitant in patients receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC). The research evaluated the measured outcomes in patients receiving these regimens.

The research primarily measured the Complete Response (CR), which studies defined as the absence of vomiting or retching and the avoidance of needing additional anti-sickness medicine. Findings describe patterns observed in the studies related to this outcome in both the acute phase (the first 24 hours post-chemo) and the delayed phase (up to 120 hours). Studies also monitored outcomes related to the severity and incidence of nausea and reported how symptoms evolved in the observed populations across multiple treatment cycles.

Evidence for Use in Postoperative Nausea and Vomiting (PONV)

Aprepitant was evaluated in controlled trials that explored its role in managing outcomes describing episodic or acute changes related to post-operative nausea and vomiting (PONV). These studies focused on short-term symptom changes in adult patients who were at a moderate or high risk for developing PONV after specific types of surgery. Research primarily examined patient-reported outcomes describing perceived discomfort over defined time intervals immediately following the procedure.

Studies monitored outcomes related to the physical discomfort of vomiting and retching during the 24 to 48 hours following surgery. They also tracked the necessity of using rescue anti-sickness medication. Research highlights changes measured during the study period for these acute symptoms. Follow-up durations were limited in this research setting.

Key Uncertainties and Research Gaps

One primary area of uncertainty lies in the distinction between outcomes related to the vomiting endpoint versus the control of nausea. While studies monitored both, findings were mixed or appeared to be less consistent for the patient-reported outcomes describing perceived discomfort related to nausea across all studies and populations. Additionally, while research was evaluated in exploring outcomes in pediatric patients, data for certain other groups, such as the elderly with multiple comorbid conditions, remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about EMEND (FAQ)

Q: What is EMEND used for?

EMEND (aprepitant) is indicated for preventing nausea and vomiting associated with certain types of cancer chemotherapy (highly and moderately emetogenic chemotherapy). It is used as part of a combination regimen with other antiemetic medicines.

Q: How does EMEND work?

EMEND is a substance P/neurokinin 1 (NK1) receptor antagonist. It is thought to work by blocking the binding of substance P at the NK1 receptors in the brain, which are involved in triggering the vomiting reflex.

Q: Can I take EMEND for general motion sickness or nausea?

EMEND is specifically approved for use in preventing nausea and vomiting associated with chemotherapy. Its use for general motion sickness, common nausea, or vomiting due to other causes is generally not supported by its approved labeling.

Q: What are the common side effects of EMEND?

Common reported side effects associated with EMEND may include tiredness, hiccups, general weakness, headache, and indigestion. It is important to discuss all potential side effects and existing conditions with a healthcare provider.

Q: Does EMEND interact with other medications?

Yes, EMEND may interact with many other medications, as it can affect the way certain drugs are metabolized (broken down) by the body. Specific drug interactions include certain corticosteroids, benzodiazepines, and hormonal contraceptives. A healthcare professional should be informed of all medications and supplements being taken.

How should EMEND be stored and disposed of?

How to Store and Dispose of EMEND?

EMEND (aprepitant) must be stored under specific conditions defined in the official regulatory labeling.

Storage Requirements

Product Form	Temperature Requirement	Stability Constraint
Capsules/Unmixed Powder	Controlled room temperature (20 C to 25 C)	Store in original packaging to protect from moisture.
Reconstituted Oral Suspension	Refrigeration (2 C to 8 C)	Do not freeze. Must be used within 72 hours of mixing.

Handling and Disposal

All forms of EMEND must be kept out of the sight and reach of children.

Disposal of unused or expired product must be carried out in accordance with local requirements. Official guidance advises against disposing of the medicine via wastewater or household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.